A gene variant responsible for vascular damage to the brain is a promising new target for drug therapy to fight...
Researchers have identified key molecular pathways which lead to late-onset Alzheimer's disease. The study presents a new approach to Alzheimer's research and highlights several potential drug targets.
A new study provides insight into the link between ApoE4 and SirT1, an anti-aging protein found is resveratrol.
A new study reports even low levels of APOE4 can increase beta-amyloid plaques in the brain and neuronal damage in mouse models of Alzheimer's disease. However, introducing APOE2 can reduce amyloid deposits and other associated damage.
Researchers have created and validated a blood test which can, with 90 percent accuracy, predict if a healthy person will develop AD within 3 years.
Researchers report ApoE4 can reduce the number of functional synapses by interfering with the DNA responsible for synapse formation and maintenance.
ApoE2 appears to have neuroprotective properties and could be key in the fight against Alzheimer's disease, according to a new study.
A new study provides evidence that a protein synonymous with Alzheimer's disease, amyloid beta, may have passed to a small group of people who were given human derived growth hormone treatments prior to the mid 1980's.